Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis

Background Idiopathic pulmonary fibrosis (IPF) is characterised by constant threat of acute exacerbation of IPF (AE-IPF). It would be significant to identify risk factors of AE-IPF. We sought to determine the prognostic value of lung transplantation candidacy testing for AE-IPF and describe explant...

Full description

Bibliographic Details
Main Authors: Yaniv Dotan, William B. Shapiro, Eneida Male, Eduardo C. Dominguez, Amandeep Aneja, Zhao Huaqing, Chandra Dass, Kartik Shenoy, Nathaniel Marchetti, Francis C. Cordova, Gerard J. Criner, A. James Mamary
Format: Article
Language:English
Published: European Respiratory Society 2020-10-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/6/4/00261-2019.full
id doaj-09dae59b1ea746e8b7c655c9780464b2
record_format Article
spelling doaj-09dae59b1ea746e8b7c655c9780464b22021-01-18T17:10:09ZengEuropean Respiratory SocietyERJ Open Research2312-05412020-10-016410.1183/23120541.00261-201900261-2019Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosisYaniv Dotan0William B. Shapiro1Eneida Male2Eduardo C. Dominguez3Amandeep Aneja4Zhao Huaqing5Chandra Dass6Kartik Shenoy7Nathaniel Marchetti8Francis C. Cordova9Gerard J. Criner10A. James Mamary11 Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Clinical Science, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Clinical Radiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Background Idiopathic pulmonary fibrosis (IPF) is characterised by constant threat of acute exacerbation of IPF (AE-IPF). It would be significant to identify risk factors of AE-IPF. We sought to determine the prognostic value of lung transplantation candidacy testing for AE-IPF and describe explant pathology of recipients with and without AE-IPF before lung transplantation. Methods Retrospective cohort study of 89 IPF patients listed for lung transplantation. Data included pulmonary function testing, echocardiography, right heart catheterisation, imaging, oesophageal pH/manometry and blood tests. Explanted tissue was evaluated by pulmonary pathologists and correlated to computed tomography (CT) findings. Results Out of 89 patients with IPF, 52 were transplanted during stable IPF and 37 had AE-IPF before transplantation (n=28) or death (n=9). There were no substantial differences in candidacy testing with and without AE-IPF. AE-IPF had higher rate of decline of forced vital capacity (FVC) (21±22% versus 4.8±14%, p=0.00019). FVC decline of >15% had a hazard ratio of 7.2 for developing AE-IPF compared to FVC decline of <5% (p=0.004). AE-IPF had more secondary diverse histopathology (82% versus 29%, p<0.0001) beyond diffuse alveolar damage. There was no correlation between ground-glass opacities (GGO) on chest CT at any point to development of AE-IPF (p=0.077), but GGO during AE-IPF predicted secondary pathological process beyond diffuse alveolar damage. Conclusions Lung transplantation candidacy testing including reflux studies did not predict AE-IPF besides FVC absolute decline. CT did not predict clinical or pathological AE-IPF. Secondary diverse lung pathology beyond diffuse alveolar damage was present in most AE-IPF, but not in stable IPF.http://openres.ersjournals.com/content/6/4/00261-2019.full
collection DOAJ
language English
format Article
sources DOAJ
author Yaniv Dotan
William B. Shapiro
Eneida Male
Eduardo C. Dominguez
Amandeep Aneja
Zhao Huaqing
Chandra Dass
Kartik Shenoy
Nathaniel Marchetti
Francis C. Cordova
Gerard J. Criner
A. James Mamary
spellingShingle Yaniv Dotan
William B. Shapiro
Eneida Male
Eduardo C. Dominguez
Amandeep Aneja
Zhao Huaqing
Chandra Dass
Kartik Shenoy
Nathaniel Marchetti
Francis C. Cordova
Gerard J. Criner
A. James Mamary
Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
ERJ Open Research
author_facet Yaniv Dotan
William B. Shapiro
Eneida Male
Eduardo C. Dominguez
Amandeep Aneja
Zhao Huaqing
Chandra Dass
Kartik Shenoy
Nathaniel Marchetti
Francis C. Cordova
Gerard J. Criner
A. James Mamary
author_sort Yaniv Dotan
title Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
title_short Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
title_full Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
title_fullStr Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
title_full_unstemmed Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
title_sort clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
publisher European Respiratory Society
series ERJ Open Research
issn 2312-0541
publishDate 2020-10-01
description Background Idiopathic pulmonary fibrosis (IPF) is characterised by constant threat of acute exacerbation of IPF (AE-IPF). It would be significant to identify risk factors of AE-IPF. We sought to determine the prognostic value of lung transplantation candidacy testing for AE-IPF and describe explant pathology of recipients with and without AE-IPF before lung transplantation. Methods Retrospective cohort study of 89 IPF patients listed for lung transplantation. Data included pulmonary function testing, echocardiography, right heart catheterisation, imaging, oesophageal pH/manometry and blood tests. Explanted tissue was evaluated by pulmonary pathologists and correlated to computed tomography (CT) findings. Results Out of 89 patients with IPF, 52 were transplanted during stable IPF and 37 had AE-IPF before transplantation (n=28) or death (n=9). There were no substantial differences in candidacy testing with and without AE-IPF. AE-IPF had higher rate of decline of forced vital capacity (FVC) (21±22% versus 4.8±14%, p=0.00019). FVC decline of >15% had a hazard ratio of 7.2 for developing AE-IPF compared to FVC decline of <5% (p=0.004). AE-IPF had more secondary diverse histopathology (82% versus 29%, p<0.0001) beyond diffuse alveolar damage. There was no correlation between ground-glass opacities (GGO) on chest CT at any point to development of AE-IPF (p=0.077), but GGO during AE-IPF predicted secondary pathological process beyond diffuse alveolar damage. Conclusions Lung transplantation candidacy testing including reflux studies did not predict AE-IPF besides FVC absolute decline. CT did not predict clinical or pathological AE-IPF. Secondary diverse lung pathology beyond diffuse alveolar damage was present in most AE-IPF, but not in stable IPF.
url http://openres.ersjournals.com/content/6/4/00261-2019.full
work_keys_str_mv AT yanivdotan clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT williambshapiro clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT eneidamale clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT eduardocdominguez clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT amandeepaneja clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT zhaohuaqing clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT chandradass clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT kartikshenoy clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT nathanielmarchetti clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT francisccordova clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT gerardjcriner clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
AT ajamesmamary clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis
_version_ 1724333042319753216